Regencell Bioscience Holdings Ltd
No SEC Form 4 filings for $RGC in the last 30 days.
Pomerantz LLP has initiated a securities class action against Regencell Bioscience, according to the article. The filing is intended to represent investors in connection with alleged securities law violations. The report does not provide specific financial figures or details on claims, but the action may be relevant to Regencell’s investors and traders.
The article is a press-release style notice in which Rosen and National Trial Lawyers encourage investors to consider legal action related to Regencell Bioscience Holdings. It does not provide specific allegations, financial figures, or case details. The notice directs questions to the company named in the release and states PR-inside is not responsible for the content.
Regencell Bioscience Holdings (NASDAQ:RGC) shares fell 5.1% on Tuesday, trading between $24.30 and $24.48 versus a prior close of $25.80. Volume was 100,662 shares, down 67% from average. Weiss Ratings reiterated a “sell (e+)” rating. The company reported $0.00 EPS in its May 8 quarter.
